Cargando…

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review

Heart failure remains a leading cause of hospitalization and death, and presents a significant challenge for healthcare providers despite the advancements in its management. This umbrella review aimed to pool the results of meta-analyses on the use of sodium-glucose cotransporter-2 (SGLT-2) inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roy, Raj, Vinjamuri, Saketh, Baskara Salian, Rishabh, Hafeez, Nosheen, Meenashi Sundaram, Dakshin, Patel, Tirath, Gudi, Thulasi Ram, Vasavada, Advait M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2023
Materias:	Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436676/ https://www.ncbi.nlm.nih.gov/pubmed/37602002 http://dx.doi.org/10.7759/cureus.42113

Ejemplares similares

The Effect of Percutaneous Coronary Intervention on QT Dispersion and the Association Between Them: A Systematic Review
por: Dahrab, Mahdi, et al.
Publicado: (2023)

Carotid Endarterectomy Versus Stenting for the Treatment of Patients With Carotid Artery Stenosis: An Updated Systematic Review and Meta-Analysis
por: Vasavada, Advait M, et al.
Publicado: (2023)

The Management of Postoperative Atrial Fibrillation (POAF): A Systematic Review
por: Meenashi Sundaram, Dakshin, et al.
Publicado: (2023)

Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review
por: Georgiou, Petros, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus
por: Srinivas, Natasha, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and Genital Infections in Patients With Diabetic Mellitus and Concomitant Coronary Artery Disease: A Single-Center Experience
por: Shah, Bhupesh R, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor Therapy for the Primary and Secondary Prevention of Heart Failure in Patients With and Without Type 2 Diabetes Mellitus: A Systematic Review
por: Wahinya, Maureen, et al.
Publicado: (2023)

Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Patients With Diabetes and Chronic Kidney Disease (CKD): A Meta-analysis of Randomized Control Trials
por: Jamil, Sidra, et al.
Publicado: (2022)

Choices and Challenges With Drug Therapy in Postural Orthostatic Tachycardia Syndrome: A Systematic Review
por: Vasavada, Advait M, et al.
Publicado: (2023)

Waterpipe Use and Its Cardiovascular Effects: A Systematic Review and Meta-Analysis of Case-Control, Cross-Sectional, and Non-Randomized Studies
por: Mahfooz, Kamran, et al.
Publicado: (2023)

A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Rao, Shiavax J, et al.
Publicado: (2022)

Multiple Dyselectrolytemia in a Chronic Alcohol Abuser: A Case Report
por: Meenashi Sundaram, Dakshin, et al.
Publicado: (2023)

Overview of Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors for the Treatment of Non-diabetic Heart Failure Patients
por: Balan, Irina, et al.
Publicado: (2021)

Effects of Sodium-Glucose Cotransporter Inhibitor Use in Type 2 Diabetes Mellitus Patients With Heart Failure
por: Choday, Silpa, et al.
Publicado: (2023)

The Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Improving Morbidity and Mortality of Heart Failure: A Systematic Review
por: Thiagaraj, Suvedha, et al.
Publicado: (2023)

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors to Decrease the Risk of Cardiovascular Diseases: A Systematic Review
por: Moparthi, Kiran Prasad, et al.
Publicado: (2023)

Benefits of Taking Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease: A Systematic Review
por: Sarker, Aditi, et al.
Publicado: (2022)

Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus
por: Rehman, Saad U, et al.
Publicado: (2020)

The Effects of Sodium-Glucose Cotransporter-2 Inhibitors (SLGT-2i) on Cardiovascular and Renal Outcomes in Non-diabetic Patients: A Systematic Review
por: Giri Ravindran, Suganya, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of the Positive Implications on Cardiovascular and Renal Health and Dynamics for Clinical Practice
por: Erdem, Saliha, et al.
Publicado: (2023)

Sodium-glucose cotransporter 2 inhibitors in obese patients with heart failure
por: Kato, Shingo, et al.
Publicado: (2023)

Do SGLT2 Inhibitors Improve Cardio-Renal Outcomes in Patients With Type II Diabetes Mellitus: A Systematic Review
por: Kalluri, Sahithi Reddy, et al.
Publicado: (2021)

Safety and Efficacy of Apixaban vs Warfarin in Patients With Stage 4 and 5 Chronic Kidney Disease: A Systematic Review
por: Fatima, Hameeda, et al.
Publicado: (2022)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes, Bryce C, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)

Early Versus Delayed Thoracic Endovascular Aortic Repair for Blunt Traumatic Aortic Injury: A Systematic Review and Meta-Analysis
por: Rudra, Pranathi, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
por: Hendryx, Michael, et al.
Publicado: (2022)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
por: Krishnan, Anoushka, et al.
Publicado: (2023)

A Systematic Review and Meta-Analysis on the Efficacy and Safety of Finerenone Therapy in Patients with Cardiovascular and Chronic Kidney Diseases in Type 2 Diabetes Mellitus
por: Jyotsna, FNU, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay
Publicado: (2016)

Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
por: Hwang, Jiwon, et al.
Publicado: (2020)

Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease
por: Nakano, Dan, et al.
Publicado: (2022)

When Zoonotic Organisms Cross Over—Trueperella pyogenes Endocarditis Presenting as a Septic Embolic Stroke
por: Deliwala, Smit, et al.
Publicado: (2020)

Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
por: Berbari, Adel E.
Publicado: (2020)

Impact of Snoring on the Cardiovascular System and its Treatment: Positive and Negative Effects of Continuous Positive Airway Pressure in Sleep Apnea
por: Jayaprakash, Thulasi Priya, et al.
Publicado: (2020)

Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis
por: Lee, Yeong-Min, et al.
Publicado: (2022)

GI inflammation Increases Sodium-Glucose Cotransporter Sglt1
por: Park, Jiyoung, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ug5sun314n9cnpltha6mnkbgcq